![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Cardinal, Biosensors Ink Distribution Deal
Cardinal, Biosensors Ink Distribution Deal
![](https://www.fdanews.com/ext/resources/test/Drug-Images2/WritingwithPencil.jpg?t=1463098653&width=430)
Cardinal Health is diving into the drug-eluting stent market, inking a distribution agreement with Biosensors to sell Biosensors’ coronary stent portfolio.
Under the agreement, Cardinal’s interventional vascular arm — Cordis — will market the stents in Europe, the Middle East, Africa, Australia and New Zealand.
Biosensors’ coronary stent portfolio includes BioFreedom, the BioMatrix NeoFlex, BioMatrix Alpha and the Chroma. — Anisa Jibrell
Upcoming Events
-
21Oct